GlassScriptPhysician profile
James Ferris Ganem
NPI 1649251380
$11,983.03
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,422 · 2020: $841 · 2021: $2,794 · 2022: $2,227 · 2023: $2,654 · 2024: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,323.64 | 2019-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| Abbott Laboratories | $1,102.26 | 2019-2024 | Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $845.34 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $772.96 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $745.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $600.79 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $562.27 | 2019-2022 | |
| Medtronic, INC. | $488.80 | 2021-2024 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $478.32 | 2019-2024 | Lifevest |
| Pfizer INC. | $386.16 | 2019-2024 | |
| Abiomed | $361.50 | 2019-2021 | |
| Amgen INC. | $347.88 | 2019-2024 | Repatha |
| Atricure, INC. | $343.94 | 2022-2024 | |
| Bardy Diagnostics, INC. | $305.00 | 2019-2022 | |
| Tactile Systems Technology INC | $238.89 | 2019-2024 | Entre Plus, Flexitouch Plus |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ganem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.